{"entity":{"id":"nct05466149","kind":"trial","name":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion","aka":[],"tldr":"A phase 2 trial of Furmonertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.","summary":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion is a phase 2 interventional study registered as NCT05466149 by Allist Pharmaceuticals, Inc., with 100 participants enrolled, started 2022-09-27 and due to reach its primary completion in 2025-06-27. Interventions recorded: Furmonertinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05466149","url":"https://clinicaltrials.gov/study/NCT05466149"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["furmonertinib"],"companies":["allist"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05466149","phase":"2","setting":"A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations","sponsor":"Allist Pharmaceuticals, Inc.","enrolled":100,"outcomes":[]},"route":"/trials/nct05466149/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/"}],"company":[{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}]}}